With regard to the effect of anti-GPC1 mAb treatment on tumor burden, although the mean total lung weights in the 10 mg/kg and 50 mg/kg anti-GPC1 mAb groups were decreased by 28% and 14% as compared with those of the control group, the differences were not statistically significant (P > 0.05. The gene discussed is GPC1; the disease is neoplasm.